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ABSTRACT 
 
The investigation of anti-atherosclerotic activity of M. parviflora and the mechanisms responsible for the extract’s 
effects (antihypolipidemic, anti-lipidperoxidation, and  monocyte chemoattractant protein-1 (MCP-1) inhibition 
activities) has been performed. In this study, atherogenesis was induced by feeding rats with a hypercholesterolemic 
diet (200 mg/Kg day-1) for 3 months. The cholesterol intake was administered along with simvastatin 3.6 mg/Kg or 
M. parvifloraextract at doses of 100, 300 and500 mg/Kg.Atheroma observation was performed by 
immunohistochemistry staining method with anti-macrophage antibody (MAC387). Animal plasma biochemical 
(total cholesterol, trigliserida, HDL, LDL, malondialdehyde, and MCP-1) profiles were measured. M. 
parvifloraextract dose dependently decreased the total-cholesterol, triglyceride, and LDL-cholesterol levels; and  
increased HDL-cholesterol in atherogenic-diet rats. Furthermore, M. parvifloraextract lowered the lipid-
peroxidation (malondilaldehyde, MDA) and MCP-1 production in dose dependent manner. Immunohistochemistry 
staining with anti-macrophage antibody(MAC387) showed that atherogenic-diet rats treated with M. 
parvifloraextract at a dose of 500 mg/Kg was not colored positively, the same as that in normal and simvastatin 
treated groups. These results suggest that M. parviflora-standardized extract may have anti-atherosclerosis effect 
throughantihiperlipidemia and antilipid-peroxidation activities. 
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INTRODUCTION 
 
Degenerative diseases such as coronary heart, stroke, and diabetes are deadly diseases and have become problems in 
both developed and developing countries. The result of Indonesia Basic Health Research in 2007 revealed that the 
prevalence of cardiovascular disease and stroke in Indonesia were 7.2% and 0.83 %, respectively [1]. The main 
process responsible for the occurence of coronary heart and stroke diseases is atherosclerosis [2].  
 
Atherosclerosis is the result of a continual inflammatory response. Inflammation is involved in all stages of 
atherosclerosis from initiation, progression, to complication of thrombosis [3, 4, 5]. Some factors that trigger 
inflammatory responses can be found in our internal and external environments such as excessive consumption of 
hydrogenated oil; obesity; smoking; exposure to radiation; toxin from environment; problems due to free radicals; 
bacterial and virus infections; emotional stress; and even some medicines [6].  
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Studies on the pathogenesis of atherosclerosis show that the alterations in endothelial-cell function precede the 
development of atherosclerotic changes and the progression of vascular lesions. Endothelial dysfunction occurs well 
before the structural manifestation of atherosclerosis and becomes an independent predictor of future cardiovascular 
events [7]. Itis a result of a continual process of endothelium layer stimulation and activation that can be caused by 
imbalanced production between oxidant and antioxidant in human body. It leads various occurences such as LDL 
oxidation  and inflammation response which worsens the condition[8].  
 
Oxidized LDL (OxLDL) produce some biological responses, firstly it induces the endothelial cell to generate some 
chemotactic substances including monocyte chemotactic protein-1(MCP-1). MCP-1attracts circulating monocytes, 
and promotes the differentiation of resident-monocytes into tissue macrophages and inhibits the motility of resident 
macrophages. These processes increase foam cell formation and finally cause atherosclerosis [9-12]. 
 
The prevention of LDL oxidation is not yet widely known. The first strategy to prevent the LDL oxidation in 
antiaterosclerotic research is mechanism-based antioxidant therapy [3]. One of the sources of natural antioxidants is 
herbal medicine with high content of polyphenol compounds. The consumption of phenolic compounds 
epidemiologically proves to have an opposite relationship with the rate of morbidity and mortality caused by the 
coronary heart disease[13].Consumption of polyphenolic-rich beverages in a short time increases the status of serum 
antioxidant in healthy subjects which is able to control cholesterol accumulation in macrophages [14]. 
 
One of the plants containing polyphenol compounds is Mezzetia parviflora Becc (M. Parviflora).  In Buton island, 
located in Eastern Indonesia, the boiled  wood bark of the plant is used to reduce cholesterol level. It is also used as 
a slimming medicine, antidiabetic, and antitumor. The effects are due to the ability of anti free-radical compound 
which is in a fairly high amount in the plant [15]. However, there is no scientific data that depict the antiatherogenic 
activity of M. parvifloraand the underlying mechanisms. Therefore, the present work is designed in order to develop 
the M. Parviflora extract to become standardized herbal that has antiatherosclerosis effects. 
 
EXPERIMENTAL SECTION 
 
Preparing the Material and Extraction 
The fresh stem bark of M. parviflora were collected locally from Buton island. After that, they were dried using 
oven in temperature of 40oC. The dried material was crushed up and ground to get homogeneous fine powder and 
then it was ready to be used as research material. A total of 5-kg of M. parviflora powder was extracted through 
maceration with ethanol-water solvent (7:3). The ethanolic extract was concentrated and evaporated until the extract 
was free from ethanol, and then lyophilized until dry extract was obtained (686.5 g). 500 g ethanolic extract ofM. 
parviflorawas subjected to a solid-liquid partition with acetone. The amount of acetone extract was 75 g and 
insoluble in acetone was 407 g. The acetone insoluble extract was standardized and used in the next test. 
 
Animals and Experimental Design 
The experimental protocols were approved by the Ethics Committee of the University of Hasanuddin, Indonesia 
(No. 0496/H04.8.4.5.31/PP36-KOMETIK/2010).  
 
Activities of M. parvifloraextract were tested by using male Wistar rat which were put in cages in a controlled 
environment. During the adaptation, rats were fed with pellet and tap water ad-libitum for 1 month until the rats 
weighing between 170-200g. The animals were randomly assigned to six experimental groups with three rats in each 
group. Animals in groups I served as positive control, was given simvastatin 3.6 mg/kg. Groups II, III, and IV were 
given sequentially 100, 300 and 500 mg/kg ofM. parvifloraextract peroral once a day. The agents were administered 
along with cholesterol 200 mg/kg administration. Group V, served as the control group, received cholesterol only. 
Rats in group VI, as the normal control, was not given any treatment. The test was performed for 3 months.  
 
Measurement of Plasma Biochemistry 
Before starting the treatment, animal plasma biochemical profiles were measured as a baseline. In the end of 
treatment, the same procedures were performed. After over night fasting (12 hours), rats were sacrificed under ether 
anesthesia and blood samples were collected intracardially into centrifuge tube. The serum were separated by 
allowing the coagulated blood to clot for 15 minutes at temperature of 25o C, centrifuged at 2500 rpm  for 20 
minutes, and then stored in plastic vials at -20oC until analysis of total cholesterol, trigliserida, HDL and LDL. Lipid 
peroxidation was estimated in serum by measuring the malondialdehyde (MDA) production generated in the 
thiobarbituric acid reaction. MCP-1 levels were only determined at the end of activities and measured by using rat 
Elisa kit (Invitrogen KRC1011).  
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Analysis of Antiaterosclerotic Effect 
The thoracic aortae of these rats were rapidly and carefully dissected from aorta ascendens arch tobifurkasi iliaka 
and then washed with cold phosphate buffer saline (PBS) containing 1 mmol/liter EDTA. Atheroma observation 
was performed by immunohistochemistry staining method with anti-macrophage antibody (MAC387). 
 
Immunohistochemistry 
Consecutive 4 µm sections were cut from each block, deparaffinized with xylene and rehydrated with graded 
ethanol solutions in deionized distilled water. Serial sections were processed for the immunohistochemical study. 
 
Immunohistochemistry was performed using the streptavidin-biotin-peroxidase method with labeled streptavidin-
biotin (LSAB; Dako, Carpinteria, USA). Briefly, the sections were placed in a glass box filled with 10 mmo l/L 
citrate buffer (pH 6.0) and were autoclaved for 15 min at 125°C to retrieve antigenicity. The sections were allowed 
to cool in the box at room temperature for 60 min before being immersed for 30 min in peroxidase blocking reagent 
(200 ml of methanol + 3.2 ml of H2O2 30%) to block  endogenous peroxidase, then immersed in antigen retrieval 
solution (Target Retrieval Solution, TRS, Dako) at 80oC and washed twice in PBS. The avidin-biotin blocking 
solution was applied to the sections for 30 min to block avidin in the tissue. The primary monoclonal rat antibody, 
anti-macrophages, macrophage marker (MAC 387)(1:100 dilution, St. Cruz Biotechnologi) was applied to sections 
and incubated overnight at 4°C in a moist chamber. Subsequently, sections were incubated with biotinylated goat 
antirabbit IgG  (Dako) for 30 min and streptavidin conjugated to horseradish peroxidase (Dako) for 30 min. 
Chromogenic fixation was carried out by immersing the sections in the solution of 3,3-diamino-benzidine 
tetrahydrochloride (DAB) (Dako) at room temperature for 10 minutes until a distinct reaction product was evident 
microscopically. The sections were then counterstained with Mayer’s hematoxylin.  Immunostaining of anti-MAC 
387 antibody was graded according to the number of stained cells and the staining intensity in individual cells as 
follows: negative (score 0), almost no positive cells; low (score 1), 1-10% of the cell showed brown staining; and 
high (score 2), over 10% of the cells showed brown staining. Immunostaining was evaluated independently by three 
independent observers who were unaware of the clinical and histological diagnoses, and all of the sections were 
scored twice to confirm the reproducibility of the results. 
 
Statistical Analysis 
The data were statistically analyzed by using SPSS (Statistical Package for Social Sciences) software for windows 
version 15.0.  The results were expressed as means ± S.D. The statistical significance of the treatments  analyzed 
with  Kruskal-wallis test and the differences between the group means was determined using the Whitney 
Test.Differences are considered significant when p<0,05 and very significant when p<0,01.  
 
RESULTS AND DISCUSSION 
 
Antihiperlipidemic and anti-lipid peroxidation Activities 
The most important risk factors of atherosclerosis and coronary heart disease (CHD) are advanced age, male gender, 
smoking, diabetes mellitus, hypertension, and hypercholesterolemia [16,17]. In this study, we investigated the 
antiatherogenic effect of M. parvifloraextract in high cholesterol fed rats. Fisrt,, the  antihiperlipidemicand anti-lipid 
peroxidation effect of M. parvifloraextract was obtained and the results can be seen in Table 1.These data showed 
that cholesterol intake (group V) for three months caused a significant increase in the total cholesterol (TC), 
triglycerides (TG), and  low density lipoprotein (LDL) as well as the decrease of high density lipoprotein (HDL) 
when compared with normal control group (group VI).  
 
The decrease of LDL level reduces cholesterol deposition in medium  artery and aortae because the LDL has a role 
to carry cholesterol from the liver to periphery cells and artery muscle cells. The increase oh HDL level helps to 
remove cells from periphery cells and to carry cholesterol back to the liver. Therefore, the increase of  HDL level is 
expected, and so is the LDL level. Besides that, LDL in an oxidated form  is caught by macrophage through a 
scavenger mechanism. Therefore, anti-arteriosclerotic medicines should be able to decrease VLDL and LDL and/or 
increase HDL. 
 
The administrations of M. parviflora extract and simvastatin to the treatment groups were able to prevent a 
hyperlipidemia condition. They significantly inhibited the elevation of plasma lipid profiles induced by dietary 
cholesterol when compared with the cholesterol control group (group V) in dose dependent manner. There were no 
significant differences between M. parviflora extract and control drug (simvastatin)  effects on LDL and HDL levels 
but not on total cholesterol and triglycerides levels. The ability of the extract to increase the HDL level and attenuate 
the LDL level causes the reduction of the atherogenic index (LDL/HDL)suggesting  that the extract may help to 
prevent the progression of atherosclerosis [18, 19]. These results are in accordance with the results of El-Adawiet al. 
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[20] who reported that grape seed extract which was rich in polyphenol compounds showed an obvious 
hypocholesterolemic effect. 
 
Table1. Test results of antihiperlipidemic and anti-lipid peroxidation effect of M. parviflora extract 
 
GROUP TREATMENT 
Average 
Percentage of 
Total Cholesterol 
Decrease 
Average 
Percentage of 
Trigliserida 
Decrease 
Average 
Percentage of 
HDL-Cholesterol 
Increase 
Average 
Percentage of 
LDL-Cholesterol 
Decrease 
Average 
Percentage of 
MDA-Decrease 
I Cholesterol 
+Simvastatin -40.31±4.46* 13.33±3.13* 126.7±15.7* -25.12±1.57* 28.72±15.86* 
II 
Cholesterol+ Extract of 
M. parviflora 
500mg/Kg 
-21.71±3.33* 18.11±1.20* 144.3±58.1* -19.88±5.47* -43.41±15.73* 
III 
Cholesterol+ Extract of 
M. parviflora 
300mg/Kg 
-12.20±6.56* 24.81±1.27* 106.1±28.6* 4.53±3.39* -27.09±9.25* 
IV 
Cholesterol+Extract of 
M. parviflora 
100mg/Kg 
-9.85±2.00* 43.56±12.16* 61.5±6.9* 11.87±0.65* 8.55±3.35* 
V Cholesterol (control) 43.09±3.11 76.56±5.97 -4.4±2.8 28.47±2.80 117.89±18.67 
VI Normal Control 3.75±2.01* 17.09±1.34* 40.0±13.9* 7.71±4.71* 15.33±7.64* 
Normal control group not given any treatment, control group received cholesterol 200 mg/kg only, the other groups were given the agents along 
with cholesterol 200 mg/kg administration. The test was performed for 3 months. *p<0.05 compared to control 
 
Hipercholesterolemia, one of the several main factors of atherosclerosis, increases the release of radicals in some 
ways. The main target of oxygen free radicals is to attack the double unsaturated fatty acid on membrane lipid to 
cause lipid peroxidation and consequently to produce the disorganization of cell structure and functions [9].  
Efficiency of antioxidant protection in a hypercholesterolemic patient depends on the balance between oxygen free 
radicals and antioxidant availability.  
 
Several studies have indicated that polyphenols (mainly catechins and procyanidins) of grape, wine, and grape seed 
extracts inhibit the oxidation of low-density lipoprotein (LDL). Tea antioxidants with a greater number of phenolic 
hydroxyl groups have greater antioxidant power, i.e.,  epigallocatechingallate (8 groups) >epicatechingallate (7 
groups) > GC (6 groups) >epicatechin (5 groups) >epigallocatechin (6 groups)[21]. Polyphenol in tea also 
haselectron-donating antioxidant characteristics whose activities are related with the amount and location of 
hydroxyl cluster that exists in the galloil cluster [22].  
 
The in vivo study of lipid peroxidation inhibition of the extract was performed by measuring the malondialdehid 
(MDA) levels  as a final product of lipid peroxidation. Dietary cholesterol produced a significant increase in plasma 
MDA levels reaching up to 117.89% of the normal values. M. parvifloraextract significantly inhibits the lipid 
peroxidation reaction in animal test dose dependently. In previous study we determined the in vitro LDL-oxidation 
inhibitory of  M. parviflora extract. The result showed that 50 µg/mlM. parviflora extract prevented  LDL oxidation 
induced by CuSO4 by prolonging the LDL-oxidation lag time (unpublished data). 
 
As a positive control, we used simvastatin. It has been reported that simvastatin has anthiatherosclerotic character 
due to its antioxidant capacity [23]. In this experiment  simvastatin  showed a significant inhibitory effect on lipid 
peroxidation but its activity was lower than the M. parviflora extract. The high potency of M. parviflora extract as 
anti lipid-peroxidation, thereby, might be expected to responsible for a preventive effect on oxidative stress related 
cardiovascular diseases.  
MCP-1 Levels 
Arteriosclerosis is a response not only to hyperlipidemia but also to the inflammations of the vessel wall. The early 
stage of atherosclerosis is characterized by the focal attachment of monocytes to the endothelium and their 
subsequent transendothelial extravasation into the vessel wall [24, 25]. One of molecules that has chemotactic 
activity for monocytes is monocyte chemoattractant protein-1 (MCP-1) [26, 27]. 
 
The following is the graph of MCP-1 content measured in rat serum after being treated with cholesterol, cholesterol 
plus simvastatin and cholesterol plus M. parviflora extract with doses of 100 mg/Kg, 300 mg/Kg and 500 mg/Kg for 
three months. 
 
Cholesterol feeding caused an increase in MCP-1 levelthat is higher compared to the normal animal group. It means 
that a high intake of cholesterol induced marked elevation of MCP-1 content. The MCP-1 levels of simvastatin and 
M. parviflora extract (500 mg/Kg) treated groupswere lower than the normal group and the cholesterol control 
group. Sparrow et al. [28] investigated the anti-inflammatory and antiatherosclerosis effect of simvastatin. They 
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found that simvastatin administered orally to mice 1 hour before carrageenan injection reduced the extent of 
carrageenan-induced foot pad edema and simvastatin prevented an increase in aortic cholesterol content. A similar 
anti-inflammatory study conducted by Marketou, et al. [29]showed that simvastatin exerted  inhibitory effects on 
oxidative stress, proinflammatory cytokines, and endothelial activation in hyperlipidemic subjects based on the 
results of serum concentrations of total peroxides (TP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-a) 
and soluble intercellular vascular adhesion molecule 1 (sICAM 1).  In our study, MCP-1 was significantly decreased 
by M. parvifloraextract 500 mg/kg-treated group, but not by M. parviflora extract at 100 mg/kg. This result 
indicated that M. parvifloraextract effectively diminished MCP-1 release at a dose of 500 mg/kg, only. Our 
preliminary study showed that M. parviflora extract (100 ppm) significantly attenuated the in vitro secretion of 
monocyte chemoattractant protein (MCP)-1 and TNF-alpha [30].   
 
Table2. The MCP-1 content Measured in Rat Blood Serum After Treatment for 3 months 
 
GROUP TREATMENT Average of Total Serum MCP-1 (pg/mL) 
I Cholesterol +Simvastatin 64493.333±2759.879* 
II Cholesterol+ Extract of M. parviflora 500mg/Kg 68233.333±2557.368* 
III Cholesterol+ Extract of M. parviflora 300mg/Kg 71033.333±1107.309* 
IV Cholesterol+Extract of M. parviflora 100mg/Kg 71613.333±1248.092ns 
V Cholesterol (control) 70293.333±1923.469 
VI Normal Control 72113.333±2955.763* 
Normal control group not given any treatment, control group received cholesterol 200 mg/kg only, the other groups were given the agents along 
with cholesterol 200 mg/kg administration. The test was performed for 3 months. *p<0.05 compared to control 
 
Some researches suggest that polyphenols have anti-inflammatory effects through modulation of the expression of 
pro-inflammatory mediators such as cyclooxygenase, lipoxygenase, NO synthase, and several important cytokines 
(nuclear factor-kappa B and mitogen-activated protein kinase signaling) [31-34]. 
 
Antiatherosclerosis Activities 
Endothelial dysfunction occurs before the structural manifestation of atherosclerosis and thus serves as an 
independent predictor of future cardiovascular events [7].The endothelial activation can be recognized from early 
monocytes adhesionin the endothelial layer so the monocytes which is initially in thecirculating monocyte system 
changing into resident monocyte andfinally differentiate into macrophage. This condition is assessed through the 
immunohistochemistry staining. The marker used ismacrophage marker (MAC 387), amonoclonal antibody, that 
detectsMacrophage migration inhibitory factor (MIF)-Related Protein MRP8/MRP14. This marker has across 
reaction with activated leukocytes (neutrophyle and monocytes)[35]and activated endothelial[36-38].Therefore, the 
monocytes, leukocytes, and activated endothelial cells appear in this immunohistochemistry staining. The cross 
reactionis due to the presence of identical epitop in the molecules, either in whole or in part [36]. This method is 
chosen because the previous study showing that 200 mg/kgBB cholesterol administration to rats every day for three 
months has not shown any formation of atherosclerotic plaque, so a marker is needed to be used for the early step of 
atherosclerosis occurrence. 
 
The following is a microscopic description of immunohistochemistry coloring results: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Endhotelial Cell Immunohistochemistry Coloring 
A. normal cells (Score 0) were shown by M. parvifloraextract 500 mg/kg-treated group which was same with normal group and simvastatin (3.6 
mg/kg)-treated group. 
B. 1% - 10% cell colored brown by monoclonal antibody  used (Score  + 1) was shown by M. parvifloraextract 100 mg/kg-treated group, 
C. > 10% cell colored brown by monoclonal antibody  used (Score + 2) was shown by the sick animal control group. 
Magnification 10 x 40 
B
  
C A 
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The results of immunohistochemistry staining show that a hypercholesterolemic diet caused an increase in the 
number of activated endothelial cell and in the amount of monocytes resident on the endothelial cell surface. It was 
scored as +2 and can be extrapolated as type I lesion in human atherosclerosis.The relationship between the score of 
endothelial dysfunction and the treatments was analyzed by using the contingency test and the chi-square value. The 
result showed that the value was larger (23.800 ) than the table value(χ20,05(12)= 21.026). It means that there was a 
relationship between endothelial dysfunction level and the treatments.  
  
The administration of M. parvifloraextract along with cholesterol can prevent the atherosclerosis occurrence in dose 
dependent manner. M. parvifloraextract 500 mg/kg-treated rats did not show the presence of brown colored cells 
stained by monoclonal antibody the same as that in the healthy animal group. The same protecting effect was shown 
by the simvastatin (3.6 mg/kg) group. Meanwhile, the animal test group treated with lower dose ofM. parviflora 
(100 mg/kg) showed that only 1-10% cells were stained by monoclonal antibody (score +1). No animals treated 
extract showed score +2 (>10% cells stained by monoclonal antibody) as in the sick animal control.   
 
M. parviflora extract consists of condensed flavonoid and tanin[15]. Therefore,  consumption ofM. parvifloraextract 
may cause accumulation of antioxidant active compounds in cells, preventing oxidation-induced cell damage and 
oxidized LDL-induced atherosclerosis plaque formation. 
 
CONCLUSION 
 
M. parviflora-standardized extract may resist the atherosclerosis process caused by the cholesterol intake through 
antihiperlipidemia and anti-lipid peroxidation activities. 
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